Get to know our clinical trials
Study of durvalumab plus tremelimumab for the treatment of refractory and progressive advanced thyroid carcinoma.
THE PURPOSE OF THIS CLINICAL TRIAL IN WHICH YOU ARE BEING OFFERED TO PARTICIPATE TODAY IS TO EVALUATE THE EFFICACY OF COMBINING IMMUNOTHERAPY WITH TREMELIMUMAB AND DURVALUMAB TO CONTROL ADVANCED THYROID TUMOR.
Technical Summary
- PHASE II STUDY OF DURVALUMAB (MEDI4736) PLUS TREMELIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED, REFRACTORY AND PROGRESSIVE THYROID CARCINOMA (DUTHY TRIAL). IMMUNOTHERAPY
- Code EudraCT: 2018-001066-42
- Protocol number: GETNE-T1812
- Promoter: GETNE
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.